Racura Oncology Ltd · ASX:RAC
Racura Oncology — Investor Presentation (November 2021)
43 slides from Racura Oncology's investor presentation, Nov 24, 2021
Slide 1: Novel RNA-Directed Therapeutics to Treat Cancer and Protect the Heart
NOVEL RNA-DIRECTED THERAPEUTICS TO TREAT CANCER AND PROTECT THE HEART Investor Presentation November 2021 RACE ONCOLOGY LIMITED (ASX:RAC) 1 INVESTOR PRESENTATION
Slide 2: Disclaimer
DISCLAIMER Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invitation f
Slide 3: Why Invest Now?
WHY INVEST NOW? Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion Zantrene® first in class, best in class, most clinically advanced FTO inhibitor Expanding projects, pipeline and prospects New formulations to extend Za
Slide 4: Significant Commercial Opportunities
SIGNIFICANT COMMERCIAL OPPORTUNITIES NEW: CARDIO- NEW: OTHER RNA ONCOLOGY PROTECTION MOLECULES Annual revenue conservatively at Existing market with millions of Expanded opportunities in US$2.6 billion for AML, renal patients given anthracyclines each oncology, cardio-protection cancer and melanoma
Slide 5: Market Rationale
MARKET RATIONALE RACE ONCOLOGY LIMITED (ASX:RAC) 5 INVESTOR PRESENTATION
Slide 6: Precision Therapy: A Fundamental Change in the Treatment of Cancer and Other Diseases
PRECISION THERAPY: A FUNDAMENTAL CHANGE IN THE TREATMENT OF CANCER AND OTHER DISEASES STANDARDISED MEDICINE PERSONALISED MEDICINE Some benefit, some do not Each patient receives the right medicine for them Patients Patients Biomarker testing (eg FTO / m6A) Therapy Personalised Therapy Benefit No Ben
Slide 7: Problems with RNA Regulation Underlie Many Diseases
PROBLEMS WITH RNA REGULATION UNDERLIE MANY DISEASES Ribonucleic acid (RNA) is the key information messenger that translates genetic instructions from DNA (genes) to cell proteins CARDIAC CELL CANCER VIRAL Targeting RNA regulation pathways, like m6A methylation, RNA DYSREGULATION IS offers new treatm
Slide 8: FTO: m6A RNA Demethylase & Regulator
FTO: m6A RNA DEMETHYLASE & REGULATOR FTO is a key m6A RNA demethylase that is dysregulated in many cancers and other diseases1,2 WRITERS Zantrene® has been independently confirmed mRNA m6A as the first-in-class, best-in-class FTO inhibitor3 ERASERS TRANSLATION Race is advancing Zantrene® as the lead
Slide 9: FTO & Cancer: Broad Commercial Potential
FTO & CANCER BROAD COMMERCIAL POTENTIAL FTO TARGETABLE TUMOURS target markets INITIAL TARGET INDICATIONS AND ESTIMATED ANNUAL REVENUE RENAL AML MELANOMA Target Est. market ($USD) indication share Estimated FTO Addressable Melanoma 5% ~$1.3BN LUNG BREAST HEAD AND Oncology Market NECK >US$120 BILLION1
Slide 10: RNA Regulation Preclinical Pharma Deals Significant Valuations
RNA REGULATION PRECLINICAL PHARMA DEALS SIGNIFICANT VALUATIONS SEP 21: OCT 21: Skyhawk raises OCT 21: Ipsen obtains an SEP 21: Exelixis deal of OCT 18: MAR 21: $600m in equity exclusive license to 858 Therapeutics US$17m upfront to Gotham Therapeutics Takeda pays $120m in funding and multiple commer
Slide 11: Corporate Strategy & Growth Plan
CORPORATE STRATEGY & GROWTH PLAN RACE ONCOLOGY LIMITED (ASX:RAC) 11 INVESTOR PRESENTATION
Slide 12: Three Pillar Strategy Optimised Building Shareholder Value
THREE PILLAR STRATEGY OPTIMISED BUILDING SHAREHOLDER VALUE Capitalising on RNA regulation leadership credentials across all 3 Pillars ZANTRENE® ZANTRENE® BEYOND 1 2 OPTIMISED 3 ZANTRENE® Maximising Current Enhancing Zantrene® Utility Pursuing New Zantrene® Formulation With New Formulations RNA-Targe
Slide 13: Expanded Pipeline Targeting FTO & m6A RNA Methylation
EXPANDED PIPELINE TARGETING FTO & m6A RNA METHYLATION PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE I PHASE II REGISTRATION r/r AML (combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (stratum 1) High Dose Zantrene + cytarabine *US IND 2022 1 EMD AML/MDS
Slide 14: Short-Term Value Drivers
SHORT-TERM VALUE DRIVERS Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 New cardio-protection patent ZANTRENE® 1 First patient into AML EMD clinical trial US IND filing for AML EMD Q3/21 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 FTO melanoma animal data New IV formulation for FTO solid tumours ZANTRENE® US IND filing for
Slide 15: Why Invest Now?
WHY INVEST NOW? Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion Zantrene® first in class, best in class, most clinically advanced FTO inhibitor Expanding projects, pipeline and prospects New formulations to extend Za
Slide 16: Pillar 1. Zantrene: Current Formulation
PILLAR 1. ZANTRENE® CURRENT FORMULATION RACE ONCOLOGY LIMITED (ASX:RAC) 16 INVESTOR PRESENTATION
Slide 17: Expanded Pipeline Targeting FTO & m6A RNA Methylation
EXPANDED PIPELINE TARGETING FTO & m6A RNA METHYLATION PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE 1 PHASE 2 REGISTRATION r/r AML (combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (stratum 1) High Dose Zantrene + cytarabine *US IND 2022 1 EMD AML/MDS (
Slide 18: R/R Acute Myeloid Leukaemia (Phase 1b/2)
1 ZANTRENE® R/R ACUTE MYELOID LEUKAEMIA (PHASE 1B/2) 2020 Phase 2 trial demonstrated an impressive 40% overall response rate for Zantrene® as a single agent in R/R AML1 CURRENT R/R AML PHASE 1B/2 • Phase 1b/2 combination study in up to 29 R/R AML patients (NCT04989335) • Regimen. Zantrene + fludarab
Slide 19: Extramedullary AML
1 ZANTRENE® EXTRAMEDULLARY AML WHY EXTRAMEDULLARY (EMD) AML? • 2020 Israel Phase 2 results - 4/4 responders had EMD AML • Unmet clinical need – EMD has poor prognosis, no approved therapies & often excluded from clinical trials • EMD AML is now known to occur in up to 20% AML patients1 • Small numbe
Slide 20: Extramedullary AML & MDS
1 ZANTRENE® EXTRAMEDULLARY AML & MDS STRATUM 2 - LOW DOSE ZANTRENE • Low dose Zantrene® with oral decitabine • Decitabine up-regulates FTO expression1 • Synergy between Zantrene® and decitabine • Trial targets AML & MDS patients that can not tolerate high intensity chemotherapy • Up to 30 patients a
Slide 21: Anthracycline Cardio-Protection
1 ZANTRENE® ANTHRACYCLINE CARDIO-PROTECTION • Heart damage from cancer therapies is a major and increasing issue as cancer patients live longer • Anthracyclines, anti-HER2, targeted agents and immuno- McGowan J et al Anthracycline Chemotherapy and Cardiotoxicity Cardiovasc Drugs therapies can all ca
Slide 22: Anthracycline Cardio-Protection Phase 2b Breast Cancer
1 ZANTRENE® ANTHRACYCLINE CARDIO-PROTECTION PHASE 2B BREAST CANCER • Commonly used anthracyclines like doxorubicin cause significant cardiac damage during cancer treatment Zantrene® & doxorubicin 100 • Prof Aaron Sverdlov & Dr Doan Ngo, University of 90 80 Newcastle 70 Cell viability (%) • Zantrene®
Slide 23: Pillar 2. Zantrene: Optimized for Targeting FTO
PILLAR 2. ZANTRENE® OPTIMIZED FOR TARGETING FTO RACE ONCOLOGY LIMITED (ASX:RAC) 23 INVESTOR PRESENTATION
Slide 24: Expanded Pipeline Targeting FTO & m6A RNA Methylation
EXPANDED PIPELINE TARGETING FTO & m6A RNA METHYLATION PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE 1 PHASE 2 REGISTRATION r/r AML (combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (stratum 1) High Dose Zantrene + cytarabine *US IND 2022 – CURRENT 1 FOR
Slide 25: Solid Tumours (Phase 1/2)
SOLID TUMOURS (PHASE 1/2) ZANTRENE® 2 OPTIMISED Zantrene® is a potent inhibitor of FTO (IC50 142nM)1 • Use as a single agent for FTO addicted cancer cells • FTO inhibition shows synergy in combination with other chemo, radio & immuno-therapy options1 • FTO inhibition overcomes resistance to chemo, r
Slide 26: Melanoma Immunotherapy Combination (Phase 1b/2)
2 ZANTRENE® OPTIMISED MELANOMA IMMUNOTHERAPY COMBINATION (PHASE 1B/2) • One of the most lethal and treatment resistant cancers with 5-year survival rate for advanced melanoma around 25%1 • FTO is overexpressed in ~50% of all metastatic melanomas and inhibition of FTO overcomes immune-therapy (checkp
Slide 27: Clear Cell Renal Cell Cancer FTO Addiction (Phase 1b/2)
2 ZANTRENE® OPTIMISED CLEAR CELL RENAL CELL CANCER FTO ADDICTION (PHASE 1B/2) • 10th most common cancer with 12% 5-year survival rate1 • 90% of ccRCC have mutations in von Hippel-Lindau (VHL) tumour suppressor gene2 • Inhibition of FTO was found to kill VHL(-) ccRCC cancers3 RACE ONCOLOGY PROGRAM •
Slide 28: Companion Diagnostics
COMPANION DIAGNOSTICS ZANTRENE® 2 OPTIMISED Companion diagnostic needed for precision medicine for both diagnosis and treatment monitoring TWO PROGRAMS UNDERWAY • FTO and global m6A RNA. Chaim Sheba, Prof Domanissi • m6A RNA genomics. University of Newcastle, Prof Murray COMPANION DIAGNOSTIC TO IDEN
Slide 29: Optimised Formulation Program: Extend and Enhance Zantrene
2 ZANTRENE® OPTIMISED FORMULATION PROGRAM. EXTEND AND ENHANCE ZANTRENE® Current Zantrene® formulation requires a two hour central line infusion Developing new Zantrene® formulations to allow peripheral infusion, shorter infusion times and less frequent administration IMPROVES ZANTRENE® UTILITY, IP P
Slide 30: Pillar 3. Beyond Zantrene
PILLAR 3. BEYOND ZANTRENE ® RACE ONCOLOGY LIMITED (ASX:RAC) 30 INVESTOR PRESENTATION
Slide 31: Expanded Pipeline Targeting FTO & m6A RNA Methylation
EXPANDED PIPELINE TARGETING FTO & m6A RNA METHYLATION PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE 1 PHASE 2 REGISTRATION r/r AML (Combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (Stratum 1) High Dose Zantrene + cytarabine *US IND 2022 1 EMD AML/MDS (
Slide 32: New m6A RNA Targeting Molecules
NEW m6A RNA TARGETING MOLECULES BEYOND 3 ZANTRENE® Recent scientific and clinical discoveries implicate m6A RNA methylation in many disease areas RACE IS DEVELOPING NEW MOLECULES TO • Allow oral administration of an FTO inhibitor • Target other m6A RNA regulator proteins • Address non-cancer indicat
Slide 33: Corporate Overview
CORPORATE OVERVIEW RACE ONCOLOGY LIMITED (ASX:RAC) 33 INVESTOR PRESENTATION
Slide 34: Strong, Experienced Board and Management Deep Domain Expertise
STRONG, EXPERIENCED BOARD AND MANAGEMENT DEEP DOMAIN EXPERTISE BOARD Dr John Cullity, Mr Phil Lynch, Dr Daniel Tillett, Mary Harney Non-Executive Chairman CEO and Managing Director CSO and Executive Director Non-Executive Director MANAGEMENT Mr Phil Lynch, Dr Daniel Tillett, PhD Dr David Fuller Dr M
Slide 35: Robust & Growing Intellectual Property Portfolio
ROBUST & GROWING INTELLECTUAL PROPERTY PORTFOLIO Patent Family PATENT STATUS OF PATENTS (US) 7234 ‘family’: the original Race Use of Zantrene and related analogues in cancer 6 granted patents 8854 ‘family’: manufacture and Manufacture and formulation of Zantrene to modern 2 pending formulation FDA s
Slide 36: Corporate Snapshot
CORPORATE SNAPSHOT ISSUED CAPITAL ASX 12 MONTH PERFORMANCE Shares1 149.5m $4.00 Options1 20.4m Shareholders2 9,272 $3.50 MARKET CAPITALISATION $3.00 Share price1 $3.77 Market value1 $564m $2.50 Cash (30 June 2021) $8.9m Enterprise value $555m $2.00 SIGNIFICANT SHAREHOLDERS $1.50 Dr Daniel Tillett (D
Slide 37: Share Purchase Plan
SHARE PURCHASE PLAN RACE ONCOLOGY LIMITED (ASX:RAC) 37 INVESTOR PRESENTATION
Slide 38: Share Purchase Plan Overview
SHARE PURCHASE PLAN OVERVIEW Race is launching a Share Purchase Plan (SPP) to provide existing shareholders the opportunity to invest in driving next steps across our highly promising clinical program. • Under the SPP, all eligible shareholders can subscribe for up to $30,000 in new RAC shares • SPP
Slide 39: Use of Funds: Base Case
USE OF FUNDS BASE CASE Proposed Expenditure FTO Solid Tumour FTO Solid Tumour (Phase 1/2) $8 million (Phase 1/2) Improved Improved Formulations $2.2 million Formulations Cardio-protection (Preclinical) Cardio-protection (Preclinical) $1 million New Molecules New Molecules $0.8 million Total $12 mill
Slide 40: Use of Funds: Mid Case
USE OF FUNDS MID CASE Proposed Expenditure FTO Solid Tumour (Phase 1/2) FTO Solid Tumour (Phase 1/2) $8 million Cardio-protection (Phase 2b) Cardio-protection (Phase 2b) $7.5 million Improved Formulations Improved Formulations $2.6 million Cardio-protection (Preclinical) Cardio-protection (Preclinic
Slide 41: Use of Funds: Full Case
USE OF FUNDS FULL CASE Proposed Expenditure FTO Solid Tumour (Phase 1/2) EMD AML (Phase 2 Europe) $9.2 million Cardio-protection (Phase 2b) FTO Solid Tumour (Phase 1/2) $8.0 million Improved Formulations Cardio-protection (Phase 2b) $7.5 million Cardio-protection (Preclinical) Improved Formulations
Slide 42: Share Purchase Plan Timetable
SHARE PURCHASE PLAN TIMETABLE* Date Item Record Date for Share Purchase Plan 8:00pm (AEDT) Monday, 22nd November 2021 Announce Share Purchase Plan, Lodge Appendix 3B and issue Tuesday, 23rd November 2021 Cleansing Notice Share Purchase Plan booklet released to ASX Tuesday, 23rd November 2021 Opening
Slide 43: RACE ONCOLOGY LIMITED (ASX:RAC) INVESTOR PRESENTATION
RACE ONCOLOGY LIMITED (ASX:RAC) 43 INVESTOR PRESENTATION
Racura Oncology — Investor Presentation (November 2021) on 6ix